Home > GAMMAGARD Products > GAMMAGARD LIQUID SC > Protection

GAMMAGARD LIQUID - SC Administration

Protecting life’s moments with sustained protection against infection1,2

In the SC administration of GAMMAGARD LIQUID clinical study:

infection-related hospitalizations per subject per year

annual rate of acute serious bacterial infections per subject per yeara

  • 3 serious validated bacterial pneumonia cases

days of missed work/school or days unable to perform normal activities per subject per year

  • Total number of subject years was 44

aThe upper 99% confidence limit of 0.133 is substantially lower than the minimal goal of achieving a rate of <1 bacterial infection per subject per year.

Subject Discontinuations in the Clinical Study2

  • One subject withdrew from the study after 10 treatments with GAMMAGARD LIQUID subcutaneous infusion (2.5 months) due to increased fatigue and malaise

References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc. 2. Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31(3):323-331.

  • Your patients can get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Find Out How
  • Clinical Study Video Learn more about the clinical study of the subcutaneous administration of GAMMAGARD LIQUID.
    View study presentation
Error processing SSI file